Exhibit 99.1 FOR IMMEDIATE RELEASE November 9, 2026 Novanta Announces Financial
Exhibit 99.1 FOR IMMEDIATE RELEASE November 9, 2026 Novanta Announces Financial Results for the Third Quarter 2026 • Third Quarter 2026 GAAP Revenue increased 23% to $305 million • Third Quarter 2026 GAAP Net Income was $2 million, and Adjusted EBITDA increased 38% to $80 million • Third Quarter 2026 GAAP Diluted EPS was $0.05, and Adjusted Diluted EPS increased 21% to $1.05 BOSTON, November 9, 2026 -- Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the third quarter 2026.
*Reconciliations of GAAP to non-GAAP financial measures, as well as definitions for the non-GAAP financial measures included in this press release and the reasons for their use, are presented below. Third Quarter “The third quarter marked a significant milestone for Novanta as we closed the largest acquisition in our history and delivered strong financial results that exceeded our expectations,” said Matthijs Glastra, Chair and Chief Executive Officer. “Momentum continued in the third quarter as revenue advanced 23% and we achieved an Adjusted EBITDA margin of 26%, which improved 290 basis points year-over- year. Customer bookings increased 29%, reflecting strong commercial momentum and providing a solid foundation for future growth, expanding our backlog to $543 million. Equally important, Riverpoint Medical is performing in line with expectations as we continue to make meaningful progress on our operational synergies, while driving an exciting new product pipeline. Collectively, these results demonstrate the strength of our strategy and our continued commitment to driving sustainable growth and long-term shareholder value.” For the third quarter of 2026, Novanta generated GAAP revenue of $305 million, an increase of $57.2 million or 23.1%, compared to prior year. The Company’s acquisition activities resulted in a net increase in revenue of $32.9 million or 13.3%. Year-over-year changes in foreign currency exchange rates unfavorably impacted revenue by $0.3 million or -0.1%. Organic Revenue Growth, which excludes the net impact of changes in foreign currency exchange rates, was an increase of 9.9% (see “Organic Revenue Growth” in the non-GAAP reconciliations below). For the third quarter of 2026, GAAP operating income was $13.9 million, compared to $21.8 million in the prior year. GAAP net income was $2.0 million, compared to $10.7 million in the prior year. GAAP diluted earnings per share (“EPS”) was $0.05, compared to $0.30 in the prior year. Diluted weighted average shares outstanding was 42.7 million for the third quarter of 2026.
Adjusted Diluted EPS increased 20.7% to $1.05, compared to $0.87 in the prior year. Adjusted EBITDA increased 38.3% to $80.3 million, compared to $58.1 million in the prior year.
Operating cash flow was $39.3 million, compared to $8.5 million in the prior year. Year-to-date operating cash flow was $155.9 million compared to $55.3 million in the prior year.
Third quarter 2026 GAAP revenue was $145 million, as compared to $125 million in the same period a year ago.
Third quarter 2026 GAAP gross profit was $73 million, as compared to $59 million in the same period a year ago. GAAP Gross profit margins was 50.2% as a percentage of revenue, as compared to 47.3% in the same period a year ago.
Third quarter 2026 GAAP revenue was $160 million, as compared to $123 million in the same period a year ago.
Third quarter 2026 GAAP gross profit was $64 million, as compared to $53 million in the same period a year ago. GAAP Gross profit margins was 39.9% as a percentage of revenue, as compared to 43.0% in the same period a year ago.
“With strong year-to-date performance and continued momentum in customer bookings, we remain on track to deliver on our full year outlook of approximately 7% Organic Revenue Growth, (or 16% on a reported basis), more than 24% growth in Adjusted EBITDA, and approximately $200 million in operating cash flow,” said Matthijs Glastra, Chair and Chief Executive Officer. “Our strong backlog, new product contributions and leading positions in markets benefiting from favorable long-term secular trends provide a solid foundation for future growth and value creation. Looking ahead to 2027, we expect reported revenue growth of more than 15%.”
For the fourth quarter of 2026, the Company expects GAAP revenue to be in the range of $306 million to $312 million, reflecting reported revenue growth of more than 18%. The Company also expects Adjusted EBITDA to be in the range of $76 million to $79 million and Adjusted Diluted EPS to be in the range of $0.91 to $0.96 per diluted share, or 0% to 5% growth. The Company’s guidance assumes no significant changes in foreign exchange rates.
For the full year 2026, the Company now expects GAAP revenue to be in the range of $1,135 million to $1,140 million, reflecting reported growth of approximately 16%. The company expects Adjusted EBITDA to be in the range of $274 million to $277 million, and Adjusted Diluted EPS to be in the range of $3.66 to $3.71 per diluted share, or 11% to 13% growth. The Company’s guidance assumes no significant changes in foreign exchange rates.
Novanta provides earnings guidance, Gross Leverage, and Net Debt Leverage on a non-GAAP basis and does not provide earnings guidance, Gross Leverage, and Net Debt Leverage on a GAAP basis, with the exception of GAAP revenue guidance. A reconciliation of the Company’s forward-looking Organic Revenue Growth, Adjusted EBITDA, Adjusted Diluted EPS, Gross Leverage, and Net Debt Leverage guidance to the most directly comparable GAAP financial measures is not provided because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including acquisitions and related expenses; impact of purchase price allocations for recently completed acquisitions; future changes in the fair value of contingent considerations; future restructuring expenses;
foreign exchange gains/(losses); significant discrete income tax expenses (benefits); benefits or expenses associated with the completion of tax audits; divestitures and related expenses; gains and losses from sale of real estate assets; costs related to product line closures; intangible asset impairment charges and related asset write-offs; and other charges reflected in the Company’s reconciliation of historical non-GAAP financial measures, the amounts of which, based on past experience, could be material. For additional information regarding Novanta’s non-GAAP financial measures, see “Use of Non- GAAP Financial Measures” below. Conference Call Information The Company will host a conference call on Tuesday, November 10, 2026 at 8:00 a.m. ET to discuss these results and to provide a business update. To access the call, please dial (888) 346-3959 prior to the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company’s website atwww.novanta.com.
A replay of the audio webcast will be available approximately three hours after the conclusion of the call in the Investor Relations section of the Company’s website atwww.novanta.com. The replay will remain available until Monday, December 28, 2026.
The non-GAAP financial measures used in this press release are Organic Revenue Growth, Adjusted Gross Profit, Adjusted Gross Profit Margin, Adjusted Operating Income, Adjusted Operating Margin, Adjusted Income Before Income Taxes, Adjusted Income Tax Provision/(Benefit) and Effective Tax Rate, Adjusted Net Income, Adjusted Diluted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Net Debt, Gross Leverage and Net Debt Leverage.
The Company believes that these non-GAAP financial measures provide useful and supplementary information to investors regarding the operating performance of the Company. It is management’s belief that these non-GAAP financial measures would be particularly useful to investors because of the significant changes that have occurred outside of the Company’s day-to-day business in accordance with the execution of the Company’s strategy. This strategy includes streamlining the Company’s existing operations through site and functional consolidations, strategic divestitures and product line closures, expanding the Company’s business through significant internal investments, and broadening the Company’s product and service offerings through acquisitions of innovative and complementary technologies and solutions. The financial impact of certain elements of these activities, particularly acquisitions, divestitures, and site and functional restructurings, is often large relative to the Company’s overall financial performance and can adversely affect the comparability of its operating results and investors’ ability to analyze the business from period to period.
The Company’s Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Profit Margin are used by management to evaluate operating performance, communicate financial results to the Board of Directors, benchmark results against historical performance and the performance of peers, and evaluate investment opportunities, including acquisitions and divestitures. In addition, Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Profit Margin are used to determine bonus payments for senior management and employees. The Company has also used in the past, and may use in the future, Adjusted Diluted EPS and Adjusted EBITDA as performance targets for certain performance-based restricted stock units. Accordingly, the Company believes that these non-GAAP financial measures provide greater transparency and insight into management’s method of analysis.
Non-GAAP financial measures should not be considered as substitutes for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on the Company’s reported results and, therefore, should not be relied upon as the sole financial measures to evaluate the Company’s financial results. The non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial measures. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables accompanying this press release.
Certain statements in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on current expectations and assumptions that are subject to risks and uncertainties. All statements contained in this news release that do not relate to matters of historical fact should be considered forward-looking statements, and are generally identified by words such as “expect,” “intend,” “anticipate,” “estimate,” “believe,” “future,” “target,” “could,” “should,” “may,” “plan,” “aim,” “outlook,” and other similar expressions. These forward-looking statements include, but are not limited to, the statements of Mr. Glastra in this press release; statements regarding anticipated financial performance and financial position, including our financial outlook for the fourth quarter and full year 2026; expectations for our future growth and prospects; statements with respect to our backlog and our momentum; expectations for our customers and for our end markets; expectations for our strategy and business model; expectations for new product launches and commercial activities; expectations with respect to productivity enhancements; expectations for margin and cash flow performance; expectations for our site regionalization strategy; the financial contributions of the Riverpoint Medical acquisition to our future results of operations and financial condition, including our leverage ratio and other pro forma financial metrics; expectations regarding the anticipated benefits of the Riverpoint Medical acquisition, including its impact on revenue, profitability, addressable market, and manufacturing strategy; expectations for capital deployment to acquisitions or other investment options; expectations regarding our liquidity and capital resources, including our ability to fund the milestone payment related to the Riverpoint Medical acquisition; and other statements that are not historical facts.
These forward-looking statements are neither promises nor guarantees, but involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various important factors, including, but not limited to, the following: economic and political conditions and the effects of these conditions on our businesses and on our customers’ businesses, capital expenditures and level of business activities; our dependence upon our ability to respond to fluctuations in product demand; our ability to continuously innovate, to introduce new products in a timely manner, and to manage transitions to new product innovations effectively; customer order timing and the effect of order delays, cancellations or changes in customer demand and other similar factors; our ability to convert backlog into revenue; disruptions or breaches in security of our or our third-party providers’ information technology systems; risks associated with our operations in foreign countries; our increased use of outsourcing in foreign countries; risks associated with increased outsourcing of components manufacturing; our exposure to increased tariffs, trade restrictions or taxes on our products; our ability to contain or reduce costs; violations of our intellectual property rights and our ability to protect our intellectual property against infringement by third parties; risk of losing our competitive advantage; our failure to successfully integrate recent and future acquisitions into our business or to realize the anticipated benefits or synergies from those acquisitions; the accuracy of financial and other information regarding Riverpoint Medical on which we relied in connection with the acquisition and our related financial projections, which was not subject to the same accounting oversight and controls as our own historical financial information; our ability to accurately forecast Riverpoint Medical's future financial performance and our ability to maintain compliance with financial covenants under our credit facility, including our leverage ratio, which depends in part on the future financial performance of the combined company; our ability to fund the milestone payment related to the Riverpoint Medical acquisition when due; our ability to attract and retain key personnel; our restructuring and realignment activities; product defects or problems integrating our products with other vendors’ products; disruptions in the supply of certain key components and other goods from our suppliers, including shortages and export restrictions; our failure to accurately forecast component and raw material requirements leading to additional costs and significant delays in shipments; production difficulties and product delivery delays or disruptions; our exposure to extensive medical device regulations, which may impede or hinder the approval, certification or sale of our products and, in some cases, may ultimately result in an inability to obtain approval or certification of certain products or may result in the recall or seizure of previously approved or certified products; the impacts of geopolitical conflicts on our business, including impacts relating to global supply chains, energy and commodity prices, financial markets and cybersecurity risks; potential penalties for violating foreign and U.S. federal and state healthcare laws and regulations; impact of healthcare industry cost containment and healthcare reform measures; changes in governmental regulations related to our business or products; actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards, and other requirements; our failure to implement new information technology systems successfully; changes in interest rates or foreign currency rates; our failure to realize the full value of our intangible assets; our reliance on original equipment manufacturer customers; the loss of sales, or significant reduction in orders from, any major customers; increasing scrutiny and changing expectations from investors, customers, governments and other stakeholders and third parties with respect to corporate
sustainability policies and practices; the effects of climate change and related regulatory responses; our exposure to the credit risk of some of our customers and in weakened markets; being subject to U.S. federal income taxation even though we are a non-U.S. corporation; changes in tax laws and fluctuations in our effective tax rates; any need for additional capital to adequately respond to business challenges or opportunities and repay or refinance our existing indebtedness, which may not be available on acceptable terms or at all; our existing indebtedness limiting our ability to engage in certain activities; volatility in the market price for our common shares; and our failure to maintain appropriate internal controls in the future.
Other important risk factors that could affect the outcome of the events set forth in these statements and that could affect the Company’s operating results and financial condition are discussed in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as updated by our subsequent filings with the Securities and Exchange Commission. Such statements are based on the Company’s beliefs and assumptions and on information currently available to the Company. The Company disclaims any obligation to publicly update or revise any such forward-looking statements as a result of developments occurring after the date of this document except as required by law.
Novanta is a leading global supplier of core technology solutions that give medical, life science, and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary expertise and competencies in precision medicine, precision manufacturing, robotics and automation, and advanced surgical technologies with a proven ability to solve complex technical challenges. This enables Novanta to engineer proprietary technology solutions that deliver extreme precision and performance, tailored to our customers' demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation, the Novanta Growth System, and our customers’ success. Novanta’s common shares are quoted on Nasdaq under the ticker symbol “NOVT.”
More information about Novanta is available on the Company’s website atwww.novanta.com. For additional information, please contact Novanta Investor Relations at (781) 266-5137 [email protected].
(781) 266-5137 NOVANTA INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands of U.S. dollars or shares, except per share amounts) (Unaudited)
Three Months Ended 2026 October 2, 2025 September 26, ────────────────────────────────────────────────────────────────────────────── Revenue $ 305,008 $ 247,836 Cost of revenue 169,370 136,915 Gross profit 135,638 110,921 Operating expenses: Research and development and 26,347 24,090 engineering Selling, general and 57,615 51,378 administrative Amortization of purchased 14,679 6,928 intangible assets Restructuring, acquisition, and 23,086 6,677 related costs Total operating 121,727 89,073 expenses Operating income 13,911 21,848 Interest income (8,284 ) (6,014 ) (expense), net Foreign exchange transaction 659 14 gains (losses), net Other income 60 (90 ) (expense), net Income before 6,346 15,758 income taxes Income tax provision 4,329 5,105 (benefit) Net Income $ 2,017 $ 10,653 Earnings per common share: Basic $ 0.05 $ 0.30 Diluted $ 0.05 $ 0.30 Weighted average common shares 42,590 35,967 outstanding—bas… Weighted average common shares 42,709 36,040 outstanding—dil…
ASSETS October 2, December 31, Current Assets 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cash and cash equivalents $ 149,218 $ 380,871 Accounts receivable, net 217,894 184,880 Inventories 220,368 188,284 Prepaid expenses and other current 34,784 28,566 assets Total current assets 622,264 782,601 Property, plant and 150,041 118,491 equipment, net Operating lease assets 55,140 41,697 Intangible assets, net 893,910 180,776 Goodwill 1,431,941 647,348 Other assets 19,750 36,193 Total assets $ 3,173,046 $ 1,807,106 LIABILITIES AND STOCKHOLDERS’ EQUITY Current Liabilities Current portion of $ 48,877 $ 38,291 long-term debt Accounts payable 99,304 94,865 Accrued expenses and other current 379,986 79,211 liabilities Total current liabilities 528,167 212,367 Long-term debt 780,949 212,538 Operating lease 49,960 38,873 liabilities Other long-term 189,461 29,041 liabilities Total liabilities 1,548,537 492,819 Stockholders’ Equity: Total stockholders’ equity 1,624,509 1,314,287 Total liabilities and stockholders’ $ 3,173,046 $ 1,807,106 equity
NOVANTA INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands of U.S. dollars) (Unaudited)
Three Months Cash flows from Ended operating October 2, September 26, activities: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net Income $ 2,017 $ 10,653 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 27,449 15,711 amortization Share-based 10,065 6,698 compensation Deferred income (5,572 ) (1,270 ) taxes Inventory acquisition 800 — fair value adjustments Other 1,748 1,706 Changes in assets and liabilities which (used)/provided cash, excluding effects from business acquisitions: Accounts (14,535 ) (10,175 ) receivable Inventories (2,029 ) (13,055 ) Other operating assets and 19,398 (1,773 ) liabilities Net cash provided by 39,341 8,495 operating activities Cash flows from investing activities: Cash paid for business acquisition, net (1,200,600 ) (1,118 ) of working capital adjustments Purchases of property, plant (8,966 ) (4,283 ) and equipment Proceeds from sale of 1,135 — property, plant and equipment Net cash used in investing (1,208,431 ) (5,401 ) activities Cash flows from financing activities: Borrowings under senior 626,000 — credit facilities Repayments of (25,311 ) (8,188 ) debt Proceeds from issuance of shares in private (428 ) — placement, net of issuance costs Payments of debt issuance (200 ) (452 ) costs Payments of withholding taxes from (395 ) (533 ) share-based awards Repurchases of — (14,056 ) common shares Other financing (214 ) (191 ) activities Net cash provided by and (used in) 599,452 (23,420 ) financing activities Effect of exchange rates on cash and 206 (365 ) cash equivalents Decrease in cash and cash (569,432 ) (20,691 ) equivalents Cash and cash equivalents, 718,650 109,912 beginning of period Cash and cash equivalents, $ 149,218 $ 89,221 end of period
NOVANTA INC. Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands of U.S. dollars) (Unaudited) Adjusted Gross Profit and Adjusted Gross Profit Margin by Reportable Segment (Non-GAAP):
Three Months Automation Ended Enabling October 2, September 26, Technologies 2026 2025 ────────────────────────────────────────────────────────────────────────────── Gross Profit $ 72,913 $ 59,214 (GAAP) Gross Profit 50.2 % 47.3 % Margin (GAAP) Amortization of intangible 1,143 1,473 assets Adjusted Gross Profit $ 74,056 $ 60,687 (Non-GAAP) Adjusted Gross Profit Margin 50.9 % 48.4 % (Non-GAAP) Medical Solutions Gross Profit $ 63,645 $ 52,697 (GAAP) Gross Profit 39.9 % 43.0 % Margin (GAAP) Amortization of intangible 5,586 2,779 assets Operational transformation 74 — costs Inventory acquisition fair 800 — value adjustments Adjusted Gross Profit $ 70,105 $ 55,476 (Non-GAAP) Adjusted Gross Profit Margin 43.9 % 45.3 % (Non-GAAP) Unallocated Gross Profit $ (920 ) $ (990 ) (GAAP) Adjusted Gross Profit $ (920 ) $ (990 ) (Non-GAAP) Novanta Inc. Gross Profit $ 135,638 $ 110,921 (GAAP) Gross Profit 44.5 % 44.8 % Margin (GAAP) Amortization of intangible 6,729 4,252 assets Operational transformation 74 — costs Inventory acquisition fair 800 — value adjustments Adjusted Gross Profit $ 143,241 $ 115,173 (Non-GAAP) Adjusted Gross Profit Margin 47.0 % 46.5 % (Non-GAAP)
NOVANTA INC. Reconciliation of GAAP to Non-GAAP Financial Measures (Amounts in thousands except per share amounts) (Unaudited) Adjusted Operating Income and Adjusted Diluted EPS (Non-GAAP):
NOVANTA INC. Reconciliation of GAAP to Non-GAAP Financial Measures (Amounts in thousands except per share amounts) (Unaudited) Adjusted Operating Income and Adjusted Diluted EPS (Non-GAAP):
NOVANTA INC. Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands of U.S. dollars) (Unaudited) Adjusted EBITDA (Non-GAAP):
Three Months Ended 2026 October 2, 2025 September 26, ────────────────────────────────────────────────────────────────────────────── Net Income $ 2,017 $ 10,653 (GAAP) Net Income 0.7 % 4.3 % Margin Interest (income) 8,284 6,014 expense, net Income tax provision 4,329 5,105 (benefit) Depreciation and 27,449 15,711 amortization Share-based 10,065 6,698 compensation Restructuring, acquisition and 22,243 6,156 related costs(1) Planning and design phase of the 3,686 3,519 financial and operation system implementation Operational transformation 921 — costs EU medical device 1,047 — regulation charges Costs incurred for insurance 221 3,042 recovery claim Inventory acquisition fair 800 — value adjustments Officer — 1,137 transition costs Other, net (719 ) 76 Adjusted EBITDA $ 80,343 $ 58,111 (Non-GAAP) Adjusted EBITDA Margin 26.3 % 23.4 % (Non-GAAP)
(1) This excludes the impact of depreciation and stock based compensation costs categorized as restructuring for the three months ended October 2, 2026 and September 26, 2025, of $0.8 million and $0.5 million, respectively. Organic Revenue Growth (Non-GAAP):
Three Months Ended October 2, 2026 ────────────────────────────────────────────────────────────────────────────── Compared to Three Months Ended September 26, 2025 Reported Revenue 23.1 % Growth/(Decline) (GAAP) Less: Change attributable to 13.3 % acquisitions Plus: Change due to foreign 0.1 % currency Organic Revenue Growth/(Decline) 9.9 % (Non-GAAP)
Non-GAAP Financial Measures The following provides additional explanations for non-GAAP financial measures used by the Company, including explanations for certain non-GAAP adjustments that may not be present in the quarterly disclosures included in the current earnings release but have been used by the Company in the two most recent fiscal years. See the tables above for the calculations of the non-GAAP financial measures used in this earnings release. Organic Revenue Growth The Company defines the term “organic revenue” as revenue excluding the impact from business acquisitions, divestitures, product line discontinuations, and the effect of foreign currency translation. The Company uses the related term “organic revenue growth” to refer to the financial performance metric of comparing current period organic revenue with the reported revenue of the corresponding period in the prior year. The Company believes that this non-GAAP financial measure, when taken together with our GAAP financial measures, allows the Company and its investors to better measure the Company’s performance and evaluate long-term performance trends. Organic revenue growth also facilitates easier comparisons of the Company’s performance with prior and future periods and relative comparisons to its peers. The Company excludes the effect of foreign currency translation from these measures because foreign currency translation is subject to volatility and can obscure underlying business trends. The Company excludes the effect of acquisitions and divestitures because these activities can vary dramatically between reporting periods and between the Company and its peers, which the Company believes makes comparisons of long-term performance trends difficult for management and investors. Organic Revenue Growth is also used as a performance metric to determine bonus payments for senior management and employees. Adjusted Gross Profit and Adjusted Gross Profit Margin The calculation of Adjusted Gross Profit and Adjusted Gross Profit Margin excludes amortization of acquired intangible assets and inventory acquisition fair value adjustments because: (i) the amounts are non-cash; (ii) the Company cannot influence the timing and amount of future expense recognition; and (iii) excluding such expenses provides investors and management better visibility into the underlying trends and performance of our businesses. The Company also excludes operational transformation costs as these costs occurred outside of the Company’s day-to-day business for the reasons described above in the introductory paragraphs of the “Use of Non-GAAP Financial Measures.” Adjusted Operating Income and Adjusted Operating Margin The calculation of Adjusted Operating Income and Adjusted Operating Margin excludes amortization of acquired intangible assets, inventory acquisition fair value adjustments, and operational transformation costs for the reasons described above for Adjusted Gross Profit and Adjusted Gross Profit Margin. The Company also excludes restructuring costs, acquisition and related costs, discrete costs related to the planning and design phase of a financial and operation system implementation, charges related to an insurance recovery claim, officer transition costs, and charges to achieve initial compliance with the EU Medical Device Regulation, as the significant charges have occurred outside of the Company’s day-to-day business for the reasons described above in the introductory paragraphs of the “Use of Non-GAAP Financial Measures.” Adjusted Income Before Income Taxes The calculation of Adjusted Income Before Income Taxes excludes amortization of acquired intangible assets, inventory acquisition fair value adjustments, operational transformation costs, restructuring, acquisition and related costs, discrete costs related to the planning and design phase of a financial and operation system implementation, charges related to an insurance recovery claim, officer transition costs, and charges to achieve initial compliance with the EU Medical Device Regulation for Adjusted Operating Income and Adjusted Operating Margin. The Company also excludes foreign exchange transaction gains (losses) as well as the write-off of costs related to our debt refinancing from the calculation of Adjusted Income Before Income Taxes as the Company cannot fully influence the timing and amount of foreign exchange transaction gains (losses).
Non-GAAP Income Tax Provision/(Benefit) and Effective Tax Rate are calculated based on the Adjusted Income Before Income Taxes by jurisdiction, the applicable tax rates in effect for the respective jurisdictions and the income tax effect of non-GAAP adjustments discussed above. In addition, the Company excludes significant discrete income tax expenses (benefits) related to releases of valuation allowances and uncertain tax positions not related to current year activity, tax audits, certain changes in tax laws, and acquisition related tax planning actions on the Company’s effective tax rate. Adjusted Net Income Because Income Before Income Taxes is included in determining Net Income, the calculation of Adjusted Net Income also excludes amortization of acquired intangible assets, inventory acquisition fair value adjustments, operational transformation costs, restructuring, acquisition and related costs, discrete costs related to the planning and design phase of a financial and operation system implementation, charges related to an insurance recovery claim, officer transition costs, charges to achieve initial compliance with the EU Medical Device Regulation, and foreign exchange transaction gains (losses) for the reasons described above for Adjusted Income Before Income Taxes. In addition, the Company excludes (i) significant discrete income tax expenses (benefits) related to releases of valuation allowances and uncertain tax positions, tax audits or amendments to prior year returns, certain changes in tax laws, and acquisition related tax planning actions on the Company’s effective tax rate; and (ii) the income tax effect of non-GAAP adjustments discussed above. Adjusted Diluted EPS Because Net Income is used in the calculation of Diluted EPS, Adjusted Diluted EPS excludes: (i) amortization of acquired intangible assets; (ii) inventory acquisition fair value adjustments; (iii) operational transformation costs; (iv) restructuring, acquisition and related costs; (v) discrete costs related to the planning and design phase of a financial and operation system implementation; (vi) charges related to an insurance recovery claim; (vii) charges to achieve initial compliance with the EU Medical Device Regulation; (viii) officer transition costs; (ix) foreign exchange transaction gains (losses); (x) significant discrete income tax expenses (benefits) related to releases of valuation allowances, uncertain tax positions, tax audits or amendments to prior year returns, certain changes in tax laws, and acquisition related tax planning actions on the Company’s effective tax rate; and (xi) the income tax effect of non-GAAP adjustments for the reasons described above for Adjusted Net Income. Adjusted EBITDA and Adjusted EBITDA Margin The Company defines Adjusted EBITDA as income before deducting interest (income) expense, income tax provision (benefit), depreciation, amortization, non-cash share-based compensation, inventory acquisition fair value adjustments, restructuring, acquisition and related costs, discrete costs related to the planning and design phase of a financial and operation system implementation, charges related to an insurance recovery claim, operational transformation costs, charges to achieve initial compliance with the EU Medical Device Regulation, officer transition costs, and other non-operating (income) expense items, including foreign exchange transaction (gains) losses, costs related to our debt refinancing and net periodic pension costs of the Company’s frozen U.K. defined benefit pension plan for the reasons described above in the introductory paragraphs of the “Use of Non-GAAP Financial Measures.”
Adjusted EBITDA Margin is defined as Adjusted EBITDA as a percentage of Revenue.
In evaluating Adjusted EBITDA and Adjusted EBITDA Margin, you should be aware that in the future the Company may incur expenses that are the same as, or similar to, some of the adjustments in this presentation. Free Cash Flow The Company defines Free Cash Flow as net cash provided by operating activities less cash paid for purchases of property, plant and equipment and plus cash proceeds from sales of property, plant and equipment. Management believes this non-GAAP financial measure is an important indicator of the Company’s liquidity as well as its ability to service its outstanding debt and to fund future growth. Net Debt, Gross Leverage and Net Debt Leverage The Company defines Net Debt as its total debt as reported on the consolidated balance sheet plus unamortized deferred financing costs and less its cash and cash equivalents as of the end of the period presented. We define Gross Leverage and Net Debt Leverage as the ratio of Total Debt and Net Debt to the last 12 months Adjusted EBITDA, which includes Adjusted EBITDA from acquisitions. Management believes Net Debt, Gross Leverage and Net Debt Leverage ratios are important measures to monitor our financial flexibility and evaluate the strength of our balance sheet. Net Debt, Gross Leverage and Net Debt Leverage ratios should not be considered in isolation or as a substitute for an analysis of our results prepared and presented in accordance with GAAP. * * * *
Full text with the tables
Exhibit 99.1 FOR IMMEDIATE RELEASE November 9, 2026 Novanta Announces Financial
Results
for the Third Quarter 2026 • Third Quarter 2026 GAAP Revenue increased 23% to
$305 million • Third Quarter 2026 GAAP Net Income was $2 million, and Adjusted
EBITDA increased 38% to $80 million • Third Quarter 2026 GAAP Diluted EPS was
$0.05, and Adjusted Diluted EPS increased 21% to $1.05 BOSTON, November 9, 2026
-- Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted
technology partner to medical and advanced technology equipment manufacturers,
today reported financial results for the third quarter 2026.
Financial Highlights
(In millions, except per Three Months Ended
share amounts) October 2, September 26,
GAAP 2026 2025
──────────────────────────────────────────────────────────────────────────────
Revenue $ 305.0 $ 247.8
Operating Income $ 13.9 $ 21.8
Net Income $ 2.0 $ 10.7
Diluted EPS $ 0.05 $ 0.30
Non-GAAP*
Adjusted Operating Income $ 65.1 $ 47.4
Adjusted Diluted EPS $ 1.05 $ 0.87
Adjusted EBITDA $ 80.3 $ 58.1
*Reconciliations of GAAP to non-GAAP financial measures, as well as definitions
for the non-GAAP financial measures included in this press release and the
reasons for their use, are presented below. Third Quarter “The third quarter
marked a significant milestone for Novanta as we closed the largest acquisition
in our history and delivered strong financial results that exceeded our
expectations,” said Matthijs Glastra, Chair and Chief Executive Officer.
“Momentum continued in the third quarter as revenue advanced 23% and we achieved
an Adjusted EBITDA margin of 26%, which improved 290 basis points year-over-
year. Customer bookings increased 29%, reflecting strong commercial momentum and
providing a solid foundation for future growth, expanding our backlog to $543
million. Equally important, Riverpoint Medical is performing in line with
expectations as we continue to make meaningful progress on our operational
synergies, while driving an exciting new product pipeline. Collectively, these
results demonstrate the strength of our strategy and our continued commitment to
driving sustainable growth and long-term shareholder value.” For the third
quarter of 2026, Novanta generated GAAP revenue of $305 million, an increase of
$57.2 million or 23.1%, compared to prior year. The Company’s acquisition
activities resulted in a net increase in revenue of $32.9 million or 13.3%.
Year-over-year changes in foreign currency exchange rates unfavorably impacted
revenue by $0.3 million or -0.1%. Organic Revenue Growth, which excludes the net
impact of changes in foreign currency exchange rates, was an increase of 9.9%
(see “Organic Revenue Growth” in the non-GAAP reconciliations below).
For the third quarter of 2026, GAAP operating income was $13.9 million, compared
to $21.8 million in the prior year. GAAP net income was $2.0 million, compared
to $10.7 million in the prior year. GAAP diluted earnings per share (“EPS”) was
$0.05, compared to $0.30 in the prior year. Diluted weighted average shares
outstanding was 42.7 million for the third quarter of 2026.
Adjusted Diluted EPS increased 20.7% to $1.05, compared to $0.87 in the prior
year. Adjusted EBITDA increased 38.3% to $80.3 million, compared to $58.1
million in the prior year.
Operating cash flow was $39.3 million, compared to $8.5 million in the prior
year. Year-to-date operating cash flow was $155.9 million compared to $55.3
million in the prior year.
Financial Overview by Reporting Segment
Automation Enabling Technologies
Third quarter 2026 GAAP revenue was $145 million, as compared to $125 million in
the same period a year ago.
Third quarter 2026 GAAP gross profit was $73 million, as compared to $59 million
in the same period a year ago. GAAP Gross profit margins was 50.2% as a
percentage of revenue, as compared to 47.3% in the same period a year ago.
Medical Solutions
Third quarter 2026 GAAP revenue was $160 million, as compared to $123 million in
the same period a year ago.
Third quarter 2026 GAAP gross profit was $64 million, as compared to $53 million
in the same period a year ago. GAAP Gross profit margins was 39.9% as a
percentage of revenue, as compared to 43.0% in the same period a year ago.
Financial Guidance
“With strong year-to-date performance and continued momentum in customer
bookings, we remain on track to deliver on our full year outlook of
approximately 7% Organic Revenue Growth, (or 16% on a reported basis), more than
24% growth in Adjusted EBITDA, and approximately $200 million in operating cash
flow,” said Matthijs Glastra, Chair and Chief Executive Officer. “Our strong
backlog, new product contributions and leading positions in markets benefiting
from favorable long-term secular trends provide a solid foundation for future
growth and value creation. Looking ahead to 2027, we expect reported revenue
growth of more than 15%.”
For the fourth quarter of 2026, the Company expects GAAP revenue to be in the
range of $306 million to $312 million, reflecting reported revenue growth of
more than 18%. The Company also expects Adjusted EBITDA to be in the range of
$76 million to $79 million and Adjusted Diluted EPS to be in the range of $0.91
to $0.96 per diluted share, or 0% to 5% growth. The Company’s guidance assumes
no significant changes in foreign exchange rates.
For the full year 2026, the Company now expects GAAP revenue to be in the range
of $1,135 million to $1,140 million, reflecting reported growth of approximately
16%. The company expects Adjusted EBITDA to be in the range of $274 million to
$277 million, and Adjusted Diluted EPS to be in the range of $3.66 to $3.71 per
diluted share, or 11% to 13% growth. The Company’s guidance assumes no
significant changes in foreign exchange rates.
Novanta provides earnings guidance, Gross Leverage, and Net Debt Leverage on a
non-GAAP basis and does not provide earnings guidance, Gross Leverage, and Net
Debt Leverage on a GAAP basis, with the exception of GAAP revenue guidance. A
reconciliation of the Company’s forward-looking Organic Revenue Growth, Adjusted
EBITDA, Adjusted Diluted EPS, Gross Leverage, and Net Debt Leverage guidance to
the most directly comparable GAAP financial measures is not provided because of
the inherent difficulty in forecasting and quantifying certain amounts that are
necessary for such reconciliations, including acquisitions and related expenses;
impact of purchase price allocations for recently completed acquisitions; future
changes in the fair value of contingent considerations; future restructuring
expenses;
foreign exchange gains/(losses); significant discrete income tax expenses
(benefits); benefits or expenses associated with the completion of tax audits;
divestitures and related expenses; gains and losses from sale of real estate
assets; costs related to product line closures; intangible asset impairment
charges and related asset write-offs; and other charges reflected in the
Company’s reconciliation of historical non-GAAP financial measures, the amounts
of which, based on past experience, could be material. For additional
information regarding Novanta’s non-GAAP financial measures, see “Use of Non-
GAAP Financial Measures” below.
Conference Call Information
The Company will host a conference call on Tuesday, November 10, 2026 at 8:00
a.m. ET to discuss these results and to provide a business update. To access the
call, please dial (888) 346-3959 prior to the scheduled conference call time.
Alternatively, the conference call can be accessed online via a live webcast on
the Events & Presentations page of the Investors section of the Company’s
website atwww.novanta.com.
A replay of the audio webcast will be available approximately three hours after
the conclusion of the call in the Investor Relations section of the Company’s
website atwww.novanta.com. The replay will remain available until Monday,
December 28, 2026.
Use of Non-GAAP Financial Measures
The non-GAAP financial measures used in this press release are Organic Revenue
Growth, Adjusted Gross Profit, Adjusted Gross Profit Margin, Adjusted Operating
Income, Adjusted Operating Margin, Adjusted Income Before Income Taxes, Adjusted
Income Tax Provision/(Benefit) and Effective Tax Rate, Adjusted Net Income,
Adjusted Diluted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow,
Net Debt, Gross Leverage and Net Debt Leverage.
The Company believes that these non-GAAP financial measures provide useful and
supplementary information to investors regarding the operating performance of
the Company. It is management’s belief that these non-GAAP financial measures
would be particularly useful to investors because of the significant changes
that have occurred outside of the Company’s day-to-day business in accordance
with the execution of the Company’s strategy. This strategy includes
streamlining the Company’s existing operations through site and functional
consolidations, strategic divestitures and product line closures, expanding the
Company’s business through significant internal investments, and broadening the
Company’s product and service offerings through acquisitions of innovative and
complementary technologies and solutions. The financial impact of certain
elements of these activities, particularly acquisitions, divestitures, and site
and functional restructurings, is often large relative to the Company’s overall
financial performance and can adversely affect the comparability of its
operating results and investors’ ability to analyze the business from period to
period.
The Company’s Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Profit
Margin are used by management to evaluate operating performance, communicate
financial results to the Board of Directors, benchmark results against
historical performance and the performance of peers, and evaluate investment
opportunities, including acquisitions and divestitures. In addition, Adjusted
EBITDA, Organic Revenue Growth and Adjusted Gross Profit Margin are used to
determine bonus payments for senior management and employees. The Company has
also used in the past, and may use in the future, Adjusted Diluted EPS and
Adjusted EBITDA as performance targets for certain performance-based restricted
stock units. Accordingly, the Company believes that these non-GAAP financial
measures provide greater transparency and insight into management’s method of
analysis.
Non-GAAP financial measures should not be considered as substitutes for, or
superior to, measures of financial performance prepared in accordance with GAAP.
They are limited in value because they exclude charges that have a material
effect on the Company’s reported results and, therefore, should not be relied
upon as the sole financial measures to evaluate the Company’s financial results.
The non-GAAP financial measures are meant to supplement, and to be viewed in
conjunction with, GAAP financial measures. Investors are encouraged to review
the reconciliation of these non-GAAP financial measures to their most directly
comparable GAAP financial measures as provided in the tables accompanying this
press release.
Safe Harbor and Forward-Looking Information
Certain statements in this release are “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995 and are based on
current expectations and assumptions that are subject to risks and
uncertainties. All statements contained in this news release that do not relate
to matters of historical fact should be considered forward-looking statements,
and are generally identified by words such as “expect,” “intend,” “anticipate,”
“estimate,” “believe,” “future,” “target,” “could,” “should,” “may,” “plan,”
“aim,” “outlook,” and other similar expressions. These forward-looking
statements include, but are not limited to, the statements of Mr. Glastra in
this press release; statements regarding anticipated financial performance and
financial position, including our financial outlook for the fourth quarter and
full year 2026; expectations for our future growth and prospects; statements
with respect to our backlog and our momentum; expectations for our customers and
for our end markets; expectations for our strategy and business model;
expectations for new product launches and commercial activities; expectations
with respect to productivity enhancements; expectations for margin and cash flow
performance; expectations for our site regionalization strategy; the financial
contributions of the Riverpoint Medical acquisition to our future results of
operations and financial condition, including our leverage ratio and other pro
forma financial metrics; expectations regarding the anticipated benefits of the
Riverpoint Medical acquisition, including its impact on revenue, profitability,
addressable market, and manufacturing strategy; expectations for capital
deployment to acquisitions or other investment options; expectations regarding
our liquidity and capital resources, including our ability to fund the milestone
payment related to the Riverpoint Medical acquisition; and other statements that
are not historical facts.
These forward-looking statements are neither promises nor guarantees, but
involve risks and uncertainties that may cause actual results to differ
materially from those contained in the forward-looking statements. Our actual
results could differ materially from those anticipated in these forward-looking
statements as a result of various important factors, including, but not limited
to, the following: economic and political conditions and the effects of these
conditions on our businesses and on our customers’ businesses, capital
expenditures and level of business activities; our dependence upon our ability
to respond to fluctuations in product demand; our ability to continuously
innovate, to introduce new products in a timely manner, and to manage
transitions to new product innovations effectively; customer order timing and
the effect of order delays, cancellations or changes in customer demand and
other similar factors; our ability to convert backlog into revenue; disruptions
or breaches in security of our or our third-party providers’ information
technology systems; risks associated with our operations in foreign countries;
our increased use of outsourcing in foreign countries; risks associated with
increased outsourcing of components manufacturing; our exposure to increased
tariffs, trade restrictions or taxes on our products; our ability to contain or
reduce costs; violations of our intellectual property rights and our ability to
protect our intellectual property against infringement by third parties; risk of
losing our competitive advantage; our failure to successfully integrate recent
and future acquisitions into our business or to realize the anticipated benefits
or synergies from those acquisitions; the accuracy of financial and other
information regarding Riverpoint Medical on which we relied in connection with
the acquisition and our related financial projections, which was not subject to
the same accounting oversight and controls as our own historical financial
information; our ability to accurately forecast Riverpoint Medical's future
financial performance and our ability to maintain compliance with financial
covenants under our credit facility, including our leverage ratio, which depends
in part on the future financial performance of the combined company; our ability
to fund the milestone payment related to the Riverpoint Medical acquisition when
due; our ability to attract and retain key personnel; our restructuring and
realignment activities; product defects or problems integrating our products
with other vendors’ products; disruptions in the supply of certain key
components and other goods from our suppliers, including shortages and export
restrictions; our failure to accurately forecast component and raw material
requirements leading to additional costs and significant delays in shipments;
production difficulties and product delivery delays or disruptions; our exposure
to extensive medical device regulations, which may impede or hinder the
approval, certification or sale of our products and, in some cases, may
ultimately result in an inability to obtain approval or certification of certain
products or may result in the recall or seizure of previously approved or
certified products; the impacts of geopolitical conflicts on our business,
including impacts relating to global supply chains, energy and commodity prices,
financial markets and cybersecurity risks; potential penalties for violating
foreign and U.S. federal and state healthcare laws and regulations; impact of
healthcare industry cost containment and healthcare reform measures; changes in
governmental regulations related to our business or products; actual or
perceived failures to comply with applicable data protection, privacy and
security laws, regulations, standards, and other requirements; our failure to
implement new information technology systems successfully; changes in interest
rates or foreign currency rates; our failure to realize the full value of our
intangible assets; our reliance on original equipment manufacturer customers;
the loss of sales, or significant reduction in orders from, any major customers;
increasing scrutiny and changing expectations from investors, customers,
governments and other stakeholders and third parties with respect to corporate
sustainability policies and practices; the effects of climate change and related
regulatory responses; our exposure to the credit risk of some of our customers
and in weakened markets; being subject to U.S. federal income taxation even
though we are a non-U.S. corporation; changes in tax laws and fluctuations in
our effective tax rates; any need for additional capital to adequately respond
to business challenges or opportunities and repay or refinance our existing
indebtedness, which may not be available on acceptable terms or at all; our
existing indebtedness limiting our ability to engage in certain activities;
volatility in the market price for our common shares; and our failure to
maintain appropriate internal controls in the future.
Other important risk factors that could affect the outcome of the events set
forth in these statements and that could affect the Company’s operating results
and financial condition are discussed in Part I, Item 1A of our Annual Report on
Form 10-K for the fiscal year ended December 31, 2025, as updated by our
subsequent filings with the Securities and Exchange Commission. Such statements
are based on the Company’s beliefs and assumptions and on information currently
available to the Company. The Company disclaims any obligation to publicly
update or revise any such forward-looking statements as a result of developments
occurring after the date of this document except as required by law.
About Novanta
Novanta is a leading global supplier of core technology solutions that give
medical, life science, and advanced industrial original equipment manufacturers
a competitive advantage. We combine deep proprietary expertise and competencies
in precision medicine, precision manufacturing, robotics and automation, and
advanced surgical technologies with a proven ability to solve complex technical
challenges. This enables Novanta to engineer proprietary technology solutions
that deliver extreme precision and performance, tailored to our customers'
demanding applications. The driving force behind our growth is the team of
innovative professionals who share a commitment to innovation, the Novanta
Growth System, and our customers’ success. Novanta’s common shares are quoted on
Nasdaq under the ticker symbol “NOVT.”
More information about Novanta is available on the Company’s website
atwww.novanta.com. For additional information, please contact Novanta Investor
Relations at (781) 266-5137 [email protected].
Novanta Inc.
Investor Relations Contact:
(781) 266-5137
NOVANTA INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands of
U.S. dollars or shares, except per share amounts) (Unaudited)
Three Months
Ended
2026 October 2, 2025 September 26,
──────────────────────────────────────────────────────────────────────────────
Revenue $ 305,008 $ 247,836
Cost of revenue 169,370 136,915
Gross profit 135,638 110,921
Operating
expenses:
Research and
development and 26,347 24,090
engineering
Selling, general
and 57,615 51,378
administrative
Amortization of
purchased 14,679 6,928
intangible
assets
Restructuring,
acquisition, and 23,086 6,677
related
costs
Total operating 121,727 89,073
expenses
Operating income 13,911 21,848
Interest income (8,284 ) (6,014 )
(expense), net
Foreign exchange
transaction 659 14
gains
(losses), net
Other income 60 (90 )
(expense), net
Income before 6,346 15,758
income taxes
Income tax
provision 4,329 5,105
(benefit)
Net Income $ 2,017 $ 10,653
Earnings per
common share:
Basic $ 0.05 $ 0.30
Diluted $ 0.05 $ 0.30
Weighted average
common shares 42,590 35,967
outstanding—bas…
Weighted average
common shares 42,709 36,040
outstanding—dil…
NOVANTA INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands of U.S.
dollars) (Unaudited)
ASSETS October 2, December 31,
Current Assets 2026 2025
──────────────────────────────────────────────────────────────────────────────
Cash and cash equivalents $ 149,218 $ 380,871
Accounts receivable, net 217,894 184,880
Inventories 220,368 188,284
Prepaid expenses and other
current 34,784 28,566
assets
Total current assets 622,264 782,601
Property, plant and 150,041 118,491
equipment, net
Operating lease assets 55,140 41,697
Intangible assets, net 893,910 180,776
Goodwill 1,431,941 647,348
Other assets 19,750 36,193
Total assets $ 3,173,046 $ 1,807,106
LIABILITIES AND
STOCKHOLDERS’ EQUITY
Current Liabilities
Current portion of $ 48,877 $ 38,291
long-term debt
Accounts payable 99,304 94,865
Accrued expenses and other
current 379,986 79,211
liabilities
Total current liabilities 528,167 212,367
Long-term debt 780,949 212,538
Operating lease 49,960 38,873
liabilities
Other long-term 189,461 29,041
liabilities
Total liabilities 1,548,537 492,819
Stockholders’ Equity:
Total stockholders’ equity 1,624,509 1,314,287
Total liabilities and
stockholders’ $ 3,173,046 $ 1,807,106
equity
NOVANTA INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands of
U.S. dollars) (Unaudited)
Three Months
Cash flows from Ended
operating October 2, September 26,
activities: 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net Income $ 2,017 $ 10,653
Adjustments to
reconcile net
income to
net cash
provided by
operating
activities:
Depreciation
and 27,449 15,711
amortization
Share-based 10,065 6,698
compensation
Deferred income (5,572 ) (1,270 )
taxes
Inventory
acquisition 800 —
fair value
adjustments
Other 1,748 1,706
Changes in
assets and
liabilities
which
(used)/provided
cash,
excluding
effects from
business
acquisitions:
Accounts (14,535 ) (10,175 )
receivable
Inventories (2,029 ) (13,055 )
Other operating
assets and 19,398 (1,773 )
liabilities
Net cash
provided by 39,341 8,495
operating
activities
Cash flows from
investing
activities:
Cash paid for
business
acquisition,
net (1,200,600 ) (1,118 )
of working
capital
adjustments
Purchases of
property, plant (8,966 ) (4,283 )
and
equipment
Proceeds from
sale of 1,135 —
property, plant
and equipment
Net cash used
in investing (1,208,431 ) (5,401 )
activities
Cash flows from
financing
activities:
Borrowings
under senior 626,000 —
credit
facilities
Repayments of (25,311 ) (8,188 )
debt
Proceeds from
issuance of
shares in
private (428 ) —
placement, net
of issuance
costs
Payments of
debt issuance (200 ) (452 )
costs
Payments of
withholding
taxes from (395 ) (533 )
share-based
awards
Repurchases of — (14,056 )
common shares
Other financing (214 ) (191 )
activities
Net cash
provided by and
(used in) 599,452 (23,420 )
financing
activities
Effect of
exchange rates
on cash and 206 (365 )
cash
equivalents
Decrease in
cash and cash (569,432 ) (20,691 )
equivalents
Cash and cash
equivalents, 718,650 109,912
beginning of
period
Cash and cash
equivalents, $ 149,218 $ 89,221
end of period
NOVANTA INC. Revenue by Reportable Segment (In thousands of U.S. dollars)
(Unaudited)
Three Months Ended
October 2, September 26,
Revenue 2026 2025
──────────────────────────────────────────────────────────────────────────────
Automation Enabling $ 145,355 $ 125,316
Technologies
Medical Solutions 159,653 122,520
Total $ 305,008 $ 247,836
NOVANTA INC. Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands
of U.S. dollars) (Unaudited) Adjusted Gross Profit and Adjusted Gross Profit
Margin by Reportable Segment (Non-GAAP):
Three Months
Automation Ended
Enabling October 2, September 26,
Technologies 2026 2025
──────────────────────────────────────────────────────────────────────────────
Gross Profit $ 72,913 $ 59,214
(GAAP)
Gross Profit 50.2 % 47.3 %
Margin (GAAP)
Amortization of
intangible 1,143 1,473
assets
Adjusted Gross
Profit $ 74,056 $ 60,687
(Non-GAAP)
Adjusted Gross
Profit Margin 50.9 % 48.4 %
(Non-GAAP)
Medical
Solutions
Gross Profit $ 63,645 $ 52,697
(GAAP)
Gross Profit 39.9 % 43.0 %
Margin (GAAP)
Amortization of
intangible 5,586 2,779
assets
Operational
transformation 74 —
costs
Inventory
acquisition fair 800 —
value
adjustments
Adjusted Gross
Profit $ 70,105 $ 55,476
(Non-GAAP)
Adjusted Gross
Profit Margin 43.9 % 45.3 %
(Non-GAAP)
Unallocated
Gross Profit $ (920 ) $ (990 )
(GAAP)
Adjusted Gross
Profit $ (920 ) $ (990 )
(Non-GAAP)
Novanta Inc.
Gross Profit $ 135,638 $ 110,921
(GAAP)
Gross Profit 44.5 % 44.8 %
Margin (GAAP)
Amortization of
intangible 6,729 4,252
assets
Operational
transformation 74 —
costs
Inventory
acquisition fair 800 —
value
adjustments
Adjusted Gross
Profit $ 143,241 $ 115,173
(Non-GAAP)
Adjusted Gross
Profit Margin 47.0 % 46.5 %
(Non-GAAP)
NOVANTA INC. Reconciliation of GAAP to Non-GAAP Financial Measures (Amounts in
thousands except per share amounts) (Unaudited) Adjusted Operating Income and
Adjusted Diluted EPS (Non-GAAP):
T…
M…
E…
O…
2,
2…
──────────────────────────────────────────────────────────────────────────────
I… I…
O… O… B… T… E… N… D…
I… M… I… P… T… I… E…
T… / R…
(…
… $ 1… 4… % $ 6… $ 4… 6… % $ … $ …
…
…
…
…
… 2… 7… % 2…
…
…
… 3… 1… % 3…
…
…
… 1… 6… % 1…
…
…
…
…
… 8… 0… % 8…
…
…
…
…
…
…
…
… 3… 1… % 3…
…
…
…
…
…
…
… 9… 0… % 9…
…
…
…
… 1… 0… % 1…
…
…
…
…
… 2… 0… % 2…
…
…
…
…
…
… (… )
…
…
…
…
…
… 7…
…
…
…
… 1…
…
…
… 5… 1… % 5… 7… … …
…
…
… $ 6… 2… % $ 5… $ 1… 2… % $ … $ …
…
…
…
… …
…
-
…
NOVANTA INC. Reconciliation of GAAP to Non-GAAP Financial Measures (Amounts in
thousands except per share amounts) (Unaudited) Adjusted Operating Income and
Adjusted Diluted EPS (Non-GAAP):
T…
M…
E…
S…
2…
2…
──────────────────────────────────────────────────────────────────────────────
I… I…
O… O… B… T… E… N… D…
I… M… I… P… T… I… E…
T… / R…
(…
… $ 2… 8… % $ 1… $ 5… 3… % $ … $ …
…
…
…
…
… 1… 4… % 1…
…
…
… 5… 2… % 5…
…
…
… 1… 0… % 1…
…
…
…
…
…
…
…
… 3… 1… % 3…
…
…
…
…
…
…
…
… 3… 1… % 3…
…
…
…
…
… 1… 0… % 1…
…
…
…
… (… )
…
…
…
…
…
… 4…
…
…
…
… 1…
…
…
… 2… 1… % 2… 4… … …
…
…
… $ 4… 1… % $ 4… $ 9… 2… % $ … $ …
…
…
…
… …
…
-
…
NOVANTA INC. Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands
of U.S. dollars) (Unaudited) Adjusted EBITDA (Non-GAAP):
Three Months
Ended
2026 October 2, 2025 September 26,
──────────────────────────────────────────────────────────────────────────────
Net Income $ 2,017 $ 10,653
(GAAP)
Net Income 0.7 % 4.3 %
Margin
Interest
(income) 8,284 6,014
expense, net
Income tax
provision 4,329 5,105
(benefit)
Depreciation and 27,449 15,711
amortization
Share-based 10,065 6,698
compensation
Restructuring,
acquisition and 22,243 6,156
related
costs(1)
Planning and
design phase of
the 3,686 3,519
financial and
operation system
implementation
Operational
transformation 921 —
costs
EU medical
device 1,047 —
regulation
charges
Costs incurred
for insurance 221 3,042
recovery
claim
Inventory
acquisition fair 800 —
value
adjustments
Officer — 1,137
transition costs
Other, net (719 ) 76
Adjusted EBITDA $ 80,343 $ 58,111
(Non-GAAP)
Adjusted EBITDA
Margin 26.3 % 23.4 %
(Non-GAAP)
(1) This excludes the impact of depreciation and stock based compensation costs
categorized as restructuring for the three months ended October 2, 2026 and
September 26, 2025, of $0.8 million and $0.5 million, respectively. Organic
Revenue Growth (Non-GAAP):
Three Months Ended October 2,
2026
──────────────────────────────────────────────────────────────────────────────
Compared to
Three Months Ended September 26,
2025
Reported Revenue 23.1 %
Growth/(Decline) (GAAP)
Less: Change attributable to 13.3 %
acquisitions
Plus: Change due to foreign 0.1 %
currency
Organic Revenue Growth/(Decline) 9.9 %
(Non-GAAP)
Net Debt (Non-GAAP):
2026 October 2, 2025 December 31,
──────────────────────────────────────────────────────────────────────────────
Total Debt (GAAP) $ 829,826 $ 250,829
Plus: Deferred financing costs 8,813 8,726
Gross Debt 838,639 259,555
Less: Cash and cash (149,218 ) (380,871 )
equivalents
Net Debt (Non-GAAP) $ 689,421 $ (121,316 )
Free Cash Flow (Non-GAAP):
Three Months
Ended
2026 October 2, 2025 September 26,
──────────────────────────────────────────────────────────────────────────────
Net Cash
Provided by
Operating $ 39,341 $ 8,495
Activities
(GAAP)
Less:
Purchases of
property, plant (8,966 ) (4,283 )
and
equipment
Plus:
Proceeds from
sale of 1,135 —
property, plant
and equipment
Free Cash Flow $ 31,510 $ 4,212
(Non-GAAP)
Non-GAAP Financial Measures
The following provides additional explanations for non-GAAP financial measures
used by the Company, including explanations for certain non-GAAP adjustments
that may not be present in the quarterly disclosures included in the current
earnings release but have been used by the Company in the two most recent fiscal
years. See the tables above for the calculations of the non-GAAP financial
measures used in this earnings release.
Organic Revenue Growth
The Company defines the term “organic revenue” as revenue excluding the impact
from business acquisitions, divestitures, product line discontinuations, and the
effect of foreign currency translation. The Company uses the related term
“organic revenue growth” to refer to the financial performance metric of
comparing current period organic revenue with the reported revenue of the
corresponding period in the prior year. The Company believes that this non-GAAP
financial measure, when taken together with our GAAP financial measures, allows
the Company and its investors to better measure the Company’s performance and
evaluate long-term performance trends. Organic revenue growth also facilitates
easier comparisons of the Company’s performance with prior and future periods
and relative comparisons to its peers. The Company excludes the effect of
foreign currency translation from these measures because foreign currency
translation is subject to volatility and can obscure underlying business trends.
The Company excludes the effect of acquisitions and divestitures because these
activities can vary dramatically between reporting periods and between the
Company and its peers, which the Company believes makes comparisons of long-term
performance trends difficult for management and investors. Organic Revenue
Growth is also used as a performance metric to determine bonus payments for
senior management and employees.
Adjusted Gross Profit and Adjusted Gross Profit Margin
The calculation of Adjusted Gross Profit and Adjusted Gross Profit Margin
excludes amortization of acquired intangible assets and inventory acquisition
fair value adjustments because: (i) the amounts are non-cash; (ii) the Company
cannot influence the timing and amount of future expense recognition; and (iii)
excluding such expenses provides investors and management better visibility into
the underlying trends and performance of our businesses. The Company also
excludes operational transformation costs as these costs occurred outside of the
Company’s day-to-day business for the reasons described above in the
introductory paragraphs of the “Use of Non-GAAP Financial Measures.”
Adjusted Operating Income and Adjusted Operating Margin
The calculation of Adjusted Operating Income and Adjusted Operating Margin
excludes amortization of acquired intangible assets, inventory acquisition fair
value adjustments, and operational transformation costs for the reasons
described above for Adjusted Gross Profit and Adjusted Gross Profit Margin. The
Company also excludes restructuring costs, acquisition and related costs,
discrete costs related to the planning and design phase of a financial and
operation system implementation, charges related to an insurance recovery claim,
officer transition costs, and charges to achieve initial compliance with the EU
Medical Device Regulation, as the significant charges have occurred outside of
the Company’s day-to-day business for the reasons described above in the
introductory paragraphs of the “Use of Non-GAAP Financial Measures.”
Adjusted Income Before Income Taxes
The calculation of Adjusted Income Before Income Taxes excludes amortization of
acquired intangible assets, inventory acquisition fair value adjustments,
operational transformation costs, restructuring, acquisition and related costs,
discrete costs related to the planning and design phase of a financial and
operation system implementation, charges related to an insurance recovery claim,
officer transition costs, and charges to achieve initial compliance with the EU
Medical Device Regulation for Adjusted Operating Income and Adjusted Operating
Margin. The Company also excludes foreign exchange transaction gains (losses) as
well as the write-off of costs related to our debt refinancing from the
calculation of Adjusted Income Before Income Taxes as the Company cannot fully
influence the timing and amount of foreign exchange transaction gains (losses).
Non-GAAP Income Tax Provision/(Benefit) and Effective Tax Rate
Non-GAAP Income Tax Provision/(Benefit) and Effective Tax Rate are calculated
based on the Adjusted Income Before Income Taxes by jurisdiction, the applicable
tax rates in effect for the respective jurisdictions and the income tax effect
of non-GAAP adjustments discussed above. In addition, the Company excludes
significant discrete income tax expenses (benefits) related to releases of
valuation allowances and uncertain tax positions not related to current year
activity, tax audits, certain changes in tax laws, and acquisition related tax
planning actions on the Company’s effective tax rate.
Adjusted Net Income
Because Income Before Income Taxes is included in determining Net Income, the
calculation of Adjusted Net Income also excludes amortization of acquired
intangible assets, inventory acquisition fair value adjustments, operational
transformation costs, restructuring, acquisition and related costs, discrete
costs related to the planning and design phase of a financial and operation
system implementation, charges related to an insurance recovery claim, officer
transition costs, charges to achieve initial compliance with the EU Medical
Device Regulation, and foreign exchange transaction gains (losses) for the
reasons described above for Adjusted Income Before Income Taxes. In addition,
the Company excludes (i) significant discrete income tax expenses (benefits)
related to releases of valuation allowances and uncertain tax positions, tax
audits or amendments to prior year returns, certain changes in tax laws, and
acquisition related tax planning actions on the Company’s effective tax rate;
and (ii) the income tax effect of non-GAAP adjustments discussed above.
Adjusted Diluted EPS
Because Net Income is used in the calculation of Diluted EPS, Adjusted Diluted
EPS excludes: (i) amortization of acquired intangible assets; (ii) inventory
acquisition fair value adjustments; (iii) operational transformation costs; (iv)
restructuring, acquisition and related costs; (v) discrete costs related to the
planning and design phase of a financial and operation system implementation;
(vi) charges related to an insurance recovery claim; (vii) charges to achieve
initial compliance with the EU Medical Device Regulation; (viii) officer
transition costs; (ix) foreign exchange transaction gains (losses); (x)
significant discrete income tax expenses (benefits) related to releases of
valuation allowances, uncertain tax positions, tax audits or amendments to prior
year returns, certain changes in tax laws, and acquisition related tax planning
actions on the Company’s effective tax rate; and (xi) the income tax effect of
non-GAAP adjustments for the reasons described above for Adjusted Net Income.
Adjusted EBITDA and Adjusted EBITDA Margin
The Company defines Adjusted EBITDA as income before deducting interest (income)
expense, income tax provision (benefit), depreciation, amortization, non-cash
share-based compensation, inventory acquisition fair value adjustments,
restructuring, acquisition and related costs, discrete costs related to the
planning and design phase of a financial and operation system implementation,
charges related to an insurance recovery claim, operational transformation
costs, charges to achieve initial compliance with the EU Medical Device
Regulation, officer transition costs, and other non-operating (income) expense
items, including foreign exchange transaction (gains) losses, costs related to
our debt refinancing and net periodic pension costs of the Company’s frozen U.K.
defined benefit pension plan for the reasons described above in the introductory
paragraphs of the “Use of Non-GAAP Financial Measures.”
Adjusted EBITDA Margin is defined as Adjusted EBITDA as a percentage of Revenue.
In evaluating Adjusted EBITDA and Adjusted EBITDA Margin, you should be aware
that in the future the Company may incur expenses that are the same as, or
similar to, some of the adjustments in this presentation.
Free Cash Flow
The Company defines Free Cash Flow as net cash provided by operating activities
less cash paid for purchases of property, plant and equipment and plus cash
proceeds from sales of property, plant and equipment. Management believes this
non-GAAP financial measure is an important indicator of the Company’s liquidity
as well as its ability to service its outstanding debt and to fund future
growth.
Net Debt, Gross Leverage and Net Debt Leverage
The Company defines Net Debt as its total debt as reported on the consolidated
balance sheet plus unamortized deferred financing costs and less its cash and
cash equivalents as of the end of the period presented. We define Gross Leverage
and Net Debt Leverage as the ratio of Total Debt and Net Debt to the last 12
months Adjusted EBITDA, which includes Adjusted EBITDA from acquisitions.
Management believes Net Debt, Gross Leverage and Net Debt Leverage ratios are
important measures to monitor our financial flexibility and evaluate the
strength of our balance sheet. Net Debt, Gross Leverage and Net Debt Leverage
ratios should not be considered in isolation or as a substitute for an analysis
of our results prepared and presented in accordance with GAAP.
* * * *